MitoAction
Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease
- This event has passed.
Expert Series: Two Generations of Mitochondrial Augmentation Technology: Clinical Advances in Treating Primary Mitochondrial Disease
November 6 @ 12:00 pm – 1:00 pm EST
Mitochondrial Augmentation Technology (MAT) involves internalizing healthy, functional mitochondria into patient-derived cells to address mitochondrial dysfunction. Minovia has developed two generations of MAT products, studied in patients with primary mitochondrial disease in collaboration with Sheba Medical Center. In this presentation, Dr. Elad Jacoby, the treating physician, and Dr. Noa Sher, Minovia’s CSO, will discuss the promises, challenges, and clinical outcomes of this innovative therapy, providing a comprehensive review of the data to date. This session offers valuable insights for patients, families, and clinicians interested in cutting-edge mitochondrial disease therapies.
About the Speaker
Elad Jacoby, MD.
Dr. Elad Jacoby is Head of Cell Therapy for Pediatric Hematology and Oncology at Sheba Medical Center, Israel, and Senior Lecturer at Tel Aviv University. A board-certified pediatric hematologist-oncologist, he leads clinical trials in advanced cellular therapies, including CAR T-cell and mitochondrial augmentation for children with cancer and mitochondrial disease. Dr. Jacoby completed fellowships at Johns Hopkins and the National Cancer Institute and is an expert in translating cell therapies from bench to bedside.
Noa Sher, Ph.D.
Dr. Noa Sher is Chief Scientific Officer at Minovia Therapeutics. A molecular and cellular biologist by training, she specializes in developing cell therapies for rare diseases, with expertise spanning bioinformatics, translational science, and clinical-stage product innovation. Dr. Sher has led R&D teams in academia and industry, including the design and execution of the first mitochondrial augmentation technology trials for mitochondrial diseases. She holds a PhD in Biochemistry from Hebrew University and performed postdoctoral research at the Whitehead Institute and the Technion.
